The National Pharmaceutical Pricing Authority (NPPA) has published a company-wise list of revised maximum retail prices (MRPs) for specified non-scheduled anti-cancer medicines. Based on information received from pharmaceutical companies up to 27 October 2026, the list provides old and revised MRPs across 543 brand, strength and pack-size entries.
The National Pharmaceutical Pricing Authority (NPPA) has released the revised MRP list for specified non-scheduled anti-cancer medicines covered under its trade margin rationalisation initiative. The document contains 543 company-wise entries, detailing the drug name, strength, dosage form, brand name, pack size, old MRP and revised MRP.
Key points include:
- The list covers formulations across several anti-cancer drug categories, including targeted therapies, hormonal therapies, immunotherapies and chemotherapy medicines.
- It includes products from multiple pharmaceutical companies, covering both branded and generic formulations.
- Revised MRPs are specified separately for individual brands, strengths, dosage forms and pack sizes.
- The list includes both reduced and unchanged MRPs, therefore, the extent of price revision varies across products.
- The revised prices are effective from 9 November 2026.
- The data is based on information received from companies up to 27 October 2026.
